These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2020-003089-38 An open-label, dose escalation, single-dose administration, multi-center phase I/II trial of FG001 (an imaging agent), in patients with glioblastoma scheduled for neurosurgery not-yet-due
Completed, report not yet due 2021-004389-37 An open-label, non-randomized, single dose, exploratory Phase II trial of FG001 (an imaging agent) for localization of biopsy-proven primary non-small cell lung cancer (NSCLC) 2023-06-02 not-yet-due
Completed, report not yet due 2022-001361-12 An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma Et åbent, ikke- ... 2023-07-10 not-yet-due
Ongoing 2023-000163-31 An open-label, non-randomized, single dose, phase II trial of FG001 (an optical imaging agent) for localization of High-Grade Gliomas, Meningiomas or presumed Low-Grade Gliomas scheduled for neurosurg... not-yet-due